var data={"title":"Gabapentin enacarbil: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Gabapentin enacarbil: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/468530?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=gabapentin-enacarbil-patient-drug-information\" class=\"drug drug_patient\">see &quot;Gabapentin enacarbil: Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12924419\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Horizant</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12732347\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticonvulsant, Miscellaneous</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12805677\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postherpetic neuralgia (PHN):</b> Oral: Initial: 600 mg once daily in the morning for 3 days, then increase to 600 mg twice daily; increasing to &gt;1200 mg daily provided no additional benefit and increased side effects</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Restless legs syndrome (RLS):</b> Oral: 600 mg once daily (at ~5:00 pm)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12805678\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. <b>Note:</b> A starting dose of 300 mg once daily for the treatment of restless leg syndrome in patients &gt;65 years has been recommended (Garcia-Borreguero 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12805679\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\"> <b>Note:</b> Estimation of renal function for the purpose of drug dosing should be done using the Cockcroft-Gault formula.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHN: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30-59 mL/minute: Initial: 300 mg every morning for 3 days, then increase to 300 mg twice daily. May increase to 600 mg twice daily as needed based on tolerability and efficacy. When discontinuing, reduce current dose to once daily in the morning for 1 week.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 15-29 mL/minute: Initial: 300 mg in the morning on day 1 and on day 3; then increase to 300 mg once daily. May increase to 300 mg twice daily if needed based on tolerability and efficacy. When discontinuing, if current dose is 300 mg twice daily, reduce to 300 mg once daily for 1 week. If current dose is 300 mg once daily, no taper is needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;15 mL/minute: 300 mg every other day in the morning; may increase dose to 300 mg  once daily if needed based on tolerability and efficacy. When discontinuing, no taper is needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;15 mL/minute and on hemodialysis: 300 mg following every dialysis. May increase to 600 mg following every dialysis if needed based on tolerability and efficacy. When discontinuing, no taper is needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RLS:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30-59 mL/minute: Initial dose: 300 mg daily; increase to 600 mg daily as needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 15-29 mL/minute: 300 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;15 mL/minute: 300 mg every other day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;15 mL/minute and on hemodialysis: Use is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15896298\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12924420\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Horizant: 300 mg, 600 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12805149\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12805146\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM250398.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV685iGigutapPyur1suViZItA==&amp;TOPIC_ID=16486\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM250398.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12805685\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Tablet should be swallowed whole; do not break, chew, cut, or crush. Administer with food. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Restless leg syndrome: Administer  at ~5:00 pm daily.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12732261\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of moderate-to-severe restless leg syndrome (RLS); management of postherpetic neuralgia (PHN)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12805161\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Percentages reported are for restless leg syndrome (RLS) 600 mg daily and postherpetic neuralgia (PHN) 1200 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Central nervous system: Drowsiness (RLS: &le;20%; PHN: &le;10%), sedation (RLS: &le;20%; PHN: &le;10%), dizziness (13% to 17%), headache (10% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (PHN: 6%; RLS: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (6%), irritability (&le;4%), insomnia (PHN: 3%), equilibrium disturbance (&lt;2%), depression (&lt;2%), disorientation (&lt;2%), intoxicated feeling (&lt;2%), lethargy (&lt;2%), vertigo (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight gain (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (6% to 8%), flatulence (&le;3%), xerostomia (&le;3%), increased appetite (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Breast hypertrophy (gabapentin), decreased libido, feeling abnormal, gynecomastia (gabapentin), increased creatine phosphokinase (gabapentin)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12805155\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed within the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12805156\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiorgan hypersensitivity: Potentially serious, sometimes fatal multiorgan hypersensitivity (also known as drug reaction with eosinophilia and systemic symptoms [DRESS]) has been reported with some antiepileptic drugs, including gabapentin. Monitor for signs and symptoms of possible disparate manifestations associated with lymphatic, hepatic, renal, cardiac, and/or hematologic systems; fever, rash, and eosinophilia may also be present. Discontinue immediately if suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal ideation: Pooled analysis of trials involving gabapentin and other antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Gabapentin enacarbil is a prodrug of gabapentin and may also increase patient&rsquo;s risk. Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dose adjustment is needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Restless legs syndrome (RLS): Not recommended for use in patients who are required to sleep during the day and remain awake during the night.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: To avoid the potential for withdrawal seizure, dose reduction is recommended for patients with postherpetic neuralgia (PHN) receiving twice daily doses or patients with RLS receiving daily doses &gt;600 mg (daily doses of &le;600 mg can be discontinued without tapering in patients with RLS).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product interchangeability: Gabapentin enacarbil (Horizant) and other gabapentin products are not interchangeable due to differences in formulation, indications and pharmacokinetics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumorigenic potential: Rat studies demonstrated an association with pancreatic adenocarcinoma (clinical implication unknown).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299374\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12817729\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16486&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the CNS depressant effect of Gabapentin Enacarbil. Alcohol (Ethyl) may increase the absorption of Gabapentin Enacarbil. Specifically, the rate of absorption may be enhanced, as alcohol may speed the release of drug from the extended-release tablet.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12805662\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Ethanol may cause rapid release of gabapentin enacarbil from the extended release tablet.  Management: Avoid ethanol. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12805151\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12805152\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Gabapentin enacarbil is the prodrug of gabapentin; bioavailability following gabapentin enacarbil is increased in comparison to gabapentin (Backonja 2011). Current guidelines note there is insufficient evidence to recommend gabapentin encarbil in pregnant women for the treatment of restless leg syndrome (Picchietti 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Refer to Gabapentin monograph for information related to gabapentin exposure during pregnancy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12805154\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if gabapentin is present in breast milk following maternal use of gabapentin enacarbil; however, gabapentin is present in breast milk following administration of other dosage forms.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Current guidelines note there is insufficient evidence to recommend gabapentin encarbil in breastfeeding women for the treatment of restless leg syndrome (Picchietti 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Refer to Gabapentin monograph for additional information related to gabapentin exposure in breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12805684\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Take with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12805687\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function (baseline and as clinically indicated); suicidality (eg, suicidal thoughts, depression, behavioral changes)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12805665\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Gabapentin enacarbil is a prodrug of gabapentin.  Gabapentin is structurally related to GABA. However, it does not bind to GABA<sub>A</sub> or GABA<sub>B</sub> receptors, and it does not appear to influence synthesis or uptake of GABA. High affinity gabapentin binding sites have been located throughout the brain; these sites correspond to the presence of voltage-gated calcium channels specifically possessing the alpha-2-delta-1 subunit. This channel appears to be located presynaptically, and may modulate the release of excitatory neurotransmitters. These effects on RLS are unknown.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12805667\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Mediated by active transport via proton-linked monocarboxylate transporter, MCT-1</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 76 L </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &lt;3% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: With food: ~75%; Fasting: 42% to 65% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Prodrug hydrolyzed primarily in the intestines to gabapentin (active metabolite)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: With food: 7.3 hours; Fasting: 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 5-6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (94%); feces (5%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322897\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Horizant Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $466.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (30): $466.24</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49939690\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Regnite (JP)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Attal N, Cruccu G, Baron R, et al, &quot;EFNS Guidelines on the Pharmacological Treatment of Neuropathic Pain: 2010 Revision,&quot; <i>Eur J Neurol</i>, 2010, 17(9):1113-e88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-enacarbil-drug-information/abstract-text/20402746/pubmed\" target=\"_blank\" id=\"20402746\">20402746</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Backonja MM, Canafax DM, and Cundy KC, &quot;Efficacy of Gabapentin Enacarbil vs Placebo in Patients With Postherpetic Neuralgia and a Pharmacokinetic Comparison With Oral Gabapentin,&quot; <i>Pain Med</i>, 2011, 12(7):1098-108.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-enacarbil-drug-information/abstract-text/21627766/pubmed\" target=\"_blank\" id=\"21627766\">21627766</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bogan RK, Bornemann MA, Kushida CA, et al, &ldquo;Long-term Maintenance Treatment of Restless Legs Syndrome With Gabapentin Enacarbil: A Randomized Controlled Study,&rdquo; <i>Mayo Clin Proc</i>, 2010, 85(6):512-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-enacarbil-drug-information/abstract-text/20511481/pubmed\" target=\"_blank\" id=\"20511481\">20511481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. <i>Sleep Med</i>. 2016;21:1-11. doi: 10.1016/j.sleep.2016.01.017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-enacarbil-drug-information/abstract-text/27448465/pubmed\" target=\"_blank\" id=\"27448465\">27448465</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garcia-Borreguero D, Stillman P, Benes H, et al, &ldquo;Algorithms for the Diagnosis and Treatment of Restless Legs Syndrome in Primary Care,&rdquo; <i>BMC Neurology</i>, 2011, 11(28): 2-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-enacarbil-drug-information/abstract-text/21352569/pubmed\" target=\"_blank\" id=\"21352569\">21352569</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Horizant (gabapentin enacarbil) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals LLC; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kushida CA, Becker PM, Ellenbogen AL, et al, &ldquo;Randomized, Double-Blind, Placebo-Controlled Study of XP13512/GSK1838262 in Patients With RLS,&rdquo; <i>Neurology</i>, 2009, 72(5):439-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-enacarbil-drug-information/abstract-text/19188575/pubmed\" target=\"_blank\" id=\"19188575\">19188575</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kushida CA, Walters AS, Becker P, et al, &ldquo;A Randomized, Double-Blind, Placebo-Controlled, Crossover Study of XP13512/GSK1838262 in the Treatment of Patients With Primary Restless Legs Syndrome,&rdquo; <i>Sleep</i>, 2009, 32(2):159-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-enacarbil-drug-information/abstract-text/19238802/pubmed\" target=\"_blank\" id=\"19238802\">19238802</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Picchietti DL, Hensley JG, Bainbridge JL, et al. Consensus clinical practice guidelines for the diagnosis and treatment of restless legs syndrome/Willis-Ekbom disease during pregnancy and lactation. <i>Sleep Med Rev</i>. 2015;22:64-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-enacarbil-drug-information/abstract-text/25553600/pubmed\" target=\"_blank\" id=\"25553600\">25553600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vignatelli L, Billiard M, Clarenbach P, et al, &ldquo;EFNS Guidelines on Management of Restless Leg Syndrome and Periodic Limb Movement Disorder in Sleep,&rdquo; <i>Eur J Neurol</i>, 2006, 13(10):1049-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-enacarbil-drug-information/abstract-text/16987157/pubmed\" target=\"_blank\" id=\"16987157\">16987157</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yaltho TC and Ondo WG, &ldquo;The Use of Gabapentin Enacarbil in the Treatment of Restless Legs Syndrome,&rdquo; <i>Ther Adv Neurol Disord</i>, 2010, 3(5):269-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-enacarbil-drug-information/abstract-text/21179617/pubmed\" target=\"_blank\" id=\"21179617\">21179617</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16486 Version 129.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F12924419\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F12732347\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F12805677\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F12805678\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F12805679\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15896298\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F12924420\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F12805149\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F12805146\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F12805685\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F12732261\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F12805161\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F12805155\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F12805156\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299374\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F12817729\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F12805662\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F12805151\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F12805152\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F12805154\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F12805684\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F12805687\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F12805665\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F12805667\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322897\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F49939690\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/16486|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=gabapentin-enacarbil-patient-drug-information\" class=\"drug drug_patient\">Gabapentin enacarbil: Patient drug information \t</a></li></ul></div></div>","javascript":null}